Checkpoint Therapeutics, Inc. (CKPT) Starts Presentation at 29th Annual ROTH Conference
Checkpoint Therapeutics (OTCQX: CKPT) is an immuno-oncology biopharmaceutical company focused on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company develops a portfolio of human immuno-oncology targeted antibodies. Its products pipeline includes Anti-PD-L1, a preclinical human antagonistic antibody designed to bind to PD-L1 and block its interaction with programmed cell death protein 1; and Anti-GITR, a human agonistic antibody that binds and triggers signaling in glucocorticoid-induced TNFR related protein expressing cells. The company is also developing CK-101, an oral covalent inhibitor, which is in preclinical stage for the treatment of…